Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes. Early use of glucocorticoids are often used as "bridge therapy" to afford clinical relief while waiting for the delay in DMARD efficacy but has also been advocated as having potential radiographic benefits down stream as well.